<< Back
Neurogen Corporation Announces Webcast of May 11 Panel at SunTrust Robinson Humphrey Therapeutic Conference

BRANFORD, Conn., May 7 /PRNewswire-FirstCall/ -- Neurogen Corporation (Nasdaq: NRGN), a drug discovery and development company, announced today that President and CEO William H. Koster, Ph.D., will present during a panel discussion at the SunTrust Robinson Humphrey Therapeutic Conference on May 11, 2004 at 3:15 p.m. EDT. Also participating will be Executive Vice President, Chief Business Officer Stephen R. Davis, ESQ. and Senior Vice President of Clinical Research and Development James V. Cassella, Ph.D. The question and answer format will be led by SunTrust Robinson Humphrey biotechnology analyst, David Witzke, Ph.D.

The Therapeutics Conference is designed to give investors the chance to meet face-to-face with the management of participating companies in an informal Q & A setting.

The panel will be webcast live from the Le Parker Meridien Hotel in New York City and may be accessed through www.suntrustrh.com or through the investor relations section of the Company's web site: www.neurogen.com.

About Neurogen Corporation

Neurogen Corporation targets new small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, currently: inflammation, pain, insomnia, depression, and obesity. Neurogen continues to generate a portfolio of compelling new drug candidates through its Accelerated Intelligent Drug Discovery (AIDD(TM)) system, its expertise in cellular functional assays, and its depth in medicinal chemistry. The Company conducts its drug research and clinical development independently or, on selected programs, collaborates with world-class pharmaceutical companies to access complementary expertise.

SOURCE Neurogen Corporation

CONTACT: Elaine Grimsell Beckwith of Neurogen Corp., +1-203-315-4615,
elaine_beckwith@nrgn.com
Web site: http://www.neurogen.com
(NRGN)